Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 11, pp 22–26 | Cite as

Schwerpunkt Pankreaskarzinom

Systemische Therapie des Pankreaskarzinoms — es hat sich viel getan

  • Rami Abbassi
  • Hana AlgülEmail author
Schwerpunkt
  • 11 Downloads

Das Pankreaskarzinom gehört trotz intensiver Bemühungen um Verbesserungen in Diagnostik und Therapie nach wie vor zu den Malignomen mit der höchsten Mortalität. Die späte Detektion des Tumors in zumeist fortgeschrittenen Stadien sowie das aggressive Voranschreiten der Erkrankung stellen wesentliche Herausforderung für die Entwicklung neuer Therapiestrategien dar. In den letzten Jahren konnten jedoch maßgebliche Fortschritte in der Behandlung des Pankreaskarzinoms erzielt werden. Ein kurzer Überblick.

Literatur

  1. 1.
    Oettle H et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77CrossRefGoogle Scholar
  2. 2.
    Neoptolemos JP et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011–24CrossRefGoogle Scholar
  3. 3.
    Conroy T et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018;36(18_suppl):Abstr LBA4001CrossRefGoogle Scholar
  4. 4.
    Tempero MA et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol. 2019;37(15_suppl):Abstr 4000CrossRefGoogle Scholar
  5. 5.
    Kunzmann V et al. Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial. Ann Oncol. 2019;30(Suppl_5):Abstr mdz247Google Scholar
  6. 6.
    van Tienhoven G et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018;36(18_suppl):Abstr LBA4002CrossRefGoogle Scholar
  7. 7.
    Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703CrossRefGoogle Scholar
  8. 8.
    Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25CrossRefGoogle Scholar
  9. 9.
    Stein SM et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114(7):737–43CrossRefGoogle Scholar
  10. 10.
    Laetitia D et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). J Clin Oncol. 2018;36(15_suppl):Abstr 4000CrossRefGoogle Scholar
  11. 11.
    Ueno H et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640–8CrossRefGoogle Scholar
  12. 12.
    Golan T et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317–27CrossRefGoogle Scholar
  13. 13.
    Oettle H et al. Second- line oxaliplatin, folinic acid, and flouoruracil versus folinic acid and flouoruracil alone for gemcitabine-refractory pancreatic cancer: outcomes Form the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423–9CrossRefGoogle Scholar
  14. 14.
    Wang-Gillam A et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–57CrossRefGoogle Scholar
  15. 15.
    Wang-Gillam A et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78–87CrossRefGoogle Scholar
  16. 16.
    Gebbia V et al. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol. 2010;33(5):461–4CrossRefGoogle Scholar
  17. 17.
    Zaniboni A et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012;69(6):1641–5CrossRefGoogle Scholar
  18. 18.
    Portal A et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113(7):989–95CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Medizinische Klinik IITechnische Universität MünchenMünchenDeutschland
  2. 2.Comprehenisve Cancer Center München am Klinikum rechts der IsarTechnische Universität MünchenMünchenDeutschland

Personalised recommendations